Perspective Therapeutics, Inc. (NYSE:CATX) Receives $15.14 Average PT from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $15.14.

Several equities analysts have weighed in on CATX shares. Royal Bank of Canada cut their target price on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, November 25th. UBS Group assumed coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target on the stock. Oppenheimer reduced their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Truist Financial assumed coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 target price (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st.

Perspective Therapeutics Stock Down 3.0 %

Shares of CATX opened at $3.19 on Wednesday. The stock’s fifty day simple moving average is $6.86 and its 200-day simple moving average is $10.79. Perspective Therapeutics has a 12-month low of $2.70 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million for the quarter. As a group, sell-side analysts predict that Perspective Therapeutics will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Johan M. Spoor acquired 8,000 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was bought at an average price of $3.77 per share, with a total value of $30,160.00. Following the transaction, the chief executive officer now directly owns 36,257 shares in the company, valued at approximately $136,688.89. The trade was a 28.31 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average price of $3.82 per share, with a total value of $49,006.78. Following the completion of the purchase, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. The trade was a 35.66 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 67,570 shares of company stock valued at $256,789 in the last 90 days. 3.52% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in Perspective Therapeutics in the 3rd quarter valued at $57,000. US Bancorp DE increased its position in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares during the period. Intech Investment Management LLC bought a new position in shares of Perspective Therapeutics in the third quarter worth $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Perspective Therapeutics in the third quarter valued at about $152,000. Finally, Los Angeles Capital Management LLC bought a new stake in Perspective Therapeutics during the third quarter worth about $153,000. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.